Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

29.17
+4.5818.63%
Post-market: 28.79-0.3764-1.29%16:58 EST
Volume:6.31M
Turnover:181.56M
Market Cap:1.70B
PE:-4.19
High:30.04
Open:28.00
Low:27.10
Close:24.59
52wk High:46.00
52wk Low:22.24
Shares:58.31M
Float Shares:51.35M
Volume Ratio:5.95
T/O Rate:12.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.9625
EPS(LYR):11.86
ROE:-27.57%
ROA:-18.71%
PB:1.32
PE(LYR):2.46

Loading ...

Agios Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Yesterday

Agios Pharmaceuticals Exec Says Aqvesme Will Be Introduced at Approximately $425,000 per Patient per Year - Conf Call

THOMSON REUTERS
·
Yesterday

BUZZ-Agios Pharma rises after US FDA expands use of co's drug for blood disorder

Reuters
·
Yesterday

Agios Pharmaceuticals Shares up 9.8% Premarket After US FDA Approves Co’s Drug for Treatment of Anemia in Adults With Blood Disorder

THOMSON REUTERS
·
Yesterday

FDA Approves Agios’ AQVESME for Anemia in Alpha- and Beta-Thalassemia

Reuters
·
Yesterday

U.S. FDA Approves Agios’ Aqvesme™ (Mitapivat) for the Treatment of Anemia in Adults With Alpha- or Beta-Thalassemia

THOMSON REUTERS
·
Yesterday

Agios Pharmaceuticals Inc - Aqvesme Expected to Be Available in Late January 2026

THOMSON REUTERS
·
Yesterday

NASDAQ TRADE HALT HALT NEWS PENDING AT 05:59 PM

Reuters
·
Yesterday

Agios Pharmaceuticals (AGIO): Reassessing Valuation After FDA Delays Thalassemia Decision for PYRUKYND Expansion

Simply Wall St.
·
Dec 11

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09

BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix

Reuters
·
Dec 08

BRIEF-Agios Pharmaceuticals Says FDA Has Not Issued Decision On Agios' sNDA for Mitapivat

Reuters
·
Dec 08

BUZZ-Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing

Reuters
·
Dec 08

Agios Pharmaceuticals Inc - FDA Has Not Issued Decision on Agios' Snda for Mitapivat

THOMSON REUTERS
·
Dec 08

Agios Pharmaceuticals Inc - FDA Has Not Provided Timeline for Regulatory Decision

THOMSON REUTERS
·
Dec 08

Agios Pharmaceuticals Inc - FDA Has Not Requested New Efficacy or Safety Data

THOMSON REUTERS
·
Dec 08

Agios Pharmaceuticals Inc - Collaborating With FDA on Labeling and Rems Materials for for Mitapivat

THOMSON REUTERS
·
Dec 08

Agios Provides Update on U.S. Snda for Mitapivat in Thalassemia

THOMSON REUTERS
·
Dec 08

Why Agios Pharmaceuticals (AGIO) May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data

Simply Wall St.
·
Nov 25

Agios Pharmaceuticals Initiated at Buy by Truist Securities

Dow Jones
·
Nov 25